Diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, and quality of life in patients with irritable bowel syndrome in Colombia

Ismael de Jesús Yepes, María Nicol Múnera, Carlos Martelo, .

Keywords: irritable bowel syndrome, oligosaccharides, disaccharides, monosaccharides, diet, quality of life

Abstract

Introduction: A growing body of evidence has pointed out the effectiveness of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) in patients with irritable bowel syndrome. However, there are no local studies to estimate the effects of this strategy on the symptoms and the health-related quality of life in these patients in Colombia or Latin America.
Objective: To determine the effect of a diet low in FODMAP on the quality of life and the severity of symptoms in patients with irritable bowel syndrome in Colombia.
Materials and methods: We collected clinical and demographic information of all patients at the time of inclusion. Immediately afterwards, a trained interviewer applied the IBS-QoL survey to estimate the quality of life of patients. Then, we evaluated the intensity of the symptoms using an analogue visual scale, before and after the diet low in FODMAP.
Results: We included 50 subjects in the final analysis. We observed an increase in all the IBS-QoL scales (average increase in overall summary: 14.7 points, 95% CI: 9.4 to 20.1; p<0.001) and a significant reduction in all symptoms (-19.8 mm; 95% CI: 23.4 mm 16.2 mm; p<0.001). Sex, age, body mass index, socioeconomic status and the health care provider were not associated with the improvement in the health-related quality of life.
Conclusion: A low diet in FODMAP reduced symptoms and improved quality of life in Colombian patients with irritable bowel syndrome. Controlled studies taking into account other factors linked to the severity of irritable bowel syndrome are required.

Downloads

Download data is not yet available.
  • Ismael de Jesús Yepes Departamento de Investigaciones, Facultad de Medicina, Universidad de Cartagena, Cartagena, Colombia Pharos, Centro de Investigaciones Biomédicas de la Costa, Cartagena, Colombia
  • María Nicol Múnera Pharos, Centro de Investigaciones Biomédicas de la Costa, Cartagena, Colombia
  • Carlos Martelo Pharos, Centro de Investigaciones Biomédicas de la Costa, Cartagena, Colombia

References

Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-80.

Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, et al. The economic consequences of irritable bowel syndrome: A US employer perspective. Arch Intern Med. 2003;163:929-35. https://doi.org/10.1001/archinte.163.8.929

Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The role of health risk factors and disease on worker productivity. J Occup Environ Med. 1999;41:863-77.

Delvaux M. Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome. Best Pract Res Clin Gastroenterol. 2004;18:747-71. https://doi.org/10.1016/j.bpg.2004.06.004

Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBSQOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study

in Poland, Egypt, México and China. Clin Drug Investig. 2014;34:783-93. https://doi.org/10.1007/s40261-014-0233-y

Jafari P, Asadollahi Z, Moini M, Seyed-Mirzaie M. Health related quality of life in iranian patients with irritable bowel syndrome: Reliability and validity of the persian version of the IBS-QOL. Iran Red Crescent Med J. 2013;15:723-8. https://doi.org/10.5812/ircmj.4605

Wong RK, Drossman DA. Quality of life measures in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010;4:277-84. https://doi.org/10.1586/egh.10.19

Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6:765-71. https://doi.org/10.1016/j.cgh.2008.02.058

Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67-75.e65.

https://doi.org/10.1053/j.gastro.2013.09.046

Molina-Infante J, Serra J, Fernández-Bañares F, Mearin F. The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. Gastroenterol Hepatol. 2016;39:55-65.

https://doi.org/10.1016/j.gastrohep.2015.07.009

Portincasa P, Bonfrate L, Scribano ML, Kohn A, Caporaso N, Festi D, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointestin Liver Dis. 2016;25:151-7. https://doi.org/10.15403/jgld.2014.1121.252.ccm

Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, et al. A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: A multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol. 2017;51:e5-e10. https://doi.org/10.1097/MCG.0000000000000528

Solem CT, Patel H, Mehta S, Mody R, Macahilig C, Gao X. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. Curr Med Res Opin. 2016;32:899-905. https://doi.org/10.1185/03007995.2016.1150262

Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;102:1442-53. https://doi.org/10.1111/j.1572-0241.2007.01283.x

Flik CE, van Rood YR, de Wit NJ. Systematic review: Knowledge and educational needs of patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2015;27:367-71. https://doi.org/10.1097/MEG.0000000000000252

Vila N, Ibáñez-Solano P, Angós-Musgo R, Betes-Ibáñez MT, Carretero-Ribón C, de la Riva-Onandía SR, et al. Pacientes con trastorno funcional intestinal: eficacia de una dieta baja en FODMAPS para el tratamiento de los síntomas digestivos. Nutrición Clínica y Dietética Hospitalaria. 2016;36:64-74.

Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S, et al. Patient educational media preferences for information about irritable bowel syndrome (IBS). Dig Dis Sci. 2008;53:3184-90. https://doi.org/10.1007/s10620-008-0280-4

Casiday RE, Hungin AP, Cornford CS, de Wit NJ, Blell MT. Patients’ explanatory models for irritable bowel syndrome: Symptoms and treatment more important than explaining aetiology. Fam Pract. 2009;26:40-7. https://doi.org/10.1093/fampra/cmn087

O’Sullivan MA, Mahmud N, Kelleher DP, Lovett E, O’Morain CA. Patient knowledge and educational needs in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2000;12:39-43.

Kanuri N, Cassell B, Bruce SE, White KS, Gott BM, Gyawali CP, et al. The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2016;28:1508-17. https://doi.org/10.1111/nmo.12848

Riddle MS, Welsh M, Porter CK, Nieh C, Boyko EJ, Gackstetter G, et al. The epidemiology of irritable bowel syndrome in the US Military: Findings from the millennium cohort study. Am J Gastroenterol. 2016;111:93-104. https://doi.org/10.1038/ajg.2015.386

Niemyjska S, Ukleja A, Lawinski M. Evaluation of irritable bowel syndrome symptoms amongst Warsaw university students. Pol Przegl Chir. 2015;87:252-9. https://doi.org/10.1515/pjs-2015-0050

Koh SJ, Kim M, Oh da Y, Kim BG, Lee KL, Kim JW. Psychosocial stress in nurses with shift work schedule is associated with functional gastrointestinal disorders. J Neurogastroenterol Motil. 2014;20:516-22. https://doi.org/10.5056/jnm14034

López-Valiente C, Cuencas-Quesada N. Dieta libre de FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) y consumo de probioticos indicados en el síndrome del intestino irritable: a propósito de un caso. Nutrición Clínica y Dietética Hospitalaria. 2016;36:194-200.

Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology 2015;149:1399-407. https://doi.org/10.1053/j.gastro.2015.07.054

Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: An update for gastroenterologists. Therap Adv Gastroenterol. 2016;9:354-

https://doi.org/10.1177/1756283X16633050

Srivastava P, Bhad R, Sharma P, Varshney M, Sharan P. Successful management of difficult-to-treat irritable bowel syndrome incorporating a psychological approach. Natl Med J India. 2015;28:188-9.

How to Cite
1.
Yepes I de J, Múnera MN, Martelo C. Diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, and quality of life in patients with irritable bowel syndrome in Colombia. biomedica [Internet]. 2018 May 1 [cited 2024 May 17];38(Sup.1):54-61. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/3443

Some similar items:

Published
2018-05-01

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code